Because it is known that TSLP induces mast cell development, prevents apoptosis in skin mast cells and it is markedly upregulated in the wheals of patients with chronic spontaneous urticaria, the anti-TSLP monoclonal antibody tezepelumab is undergoing clinical trial assessments for this disease [83]. Here, TSLP is linked to chronic idiopathic urticaria.